Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

Bavarian Nordic has supplied a liquid-frozen formulation of JYNNEOS to the U.S. government for stockpiling since 2010 and in ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q1 2025 Results, Conference Call and Webcast. At this time all participants will be in a listen-only mode. After the speaker ...

COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...